Elaine brings to Moonwalk Biosciences more than 20 years of business experience in the life sciences, focused on corporate & business development, pharma transactions, corporate strategy, fundraising, and operations. She was most recently SVP Business Development & Corporate Strategy at Lyell Immunopharma, where she led all business development, alliance management, and early commercial functions such as competitive intelligence and new product & portfolio planning, as well as having played a major role in Lyell’s IPO. Prior to Lyell, she was a VP at Mindstrong Health, leading operations, communications and marketing/policy. Before that, Elaine was a founding employee and Head of Business Development at GRAIL, having led the operational spin-out from Illumina. At GRAIL, she implemented the partnerships that enabled large scale clinical trials, and the strategic pharma collaborations and investments that comprised a major portion of GRAIL’s record-breaking $900M+ Series B financing. Elaine spent several years as Director of Business Development at Illumina advancing the company’s clinical product strategies, as well as Genomic Health (now Exact Sciences) where she focused on growing the company’s OncoType Dx™ product portfolio in multiple disease indications and international commercial expansion. Elaine earned a B.S. in Biological Sciences and an M.S. in Management Science & Engineering, both from Stanford University, where she was also a Mayfield Fund Fellow.